vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 0.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
ESPR vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $300.5M |
| Net Profit | — | $39.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 13.0% |
| Revenue YoY | 143.7% | — |
| Net Profit YoY | — | -12.4% |
| EPS (diluted) | $0.32 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $168.4M | $329.9M | ||
| Q3 25 | $87.3M | $330.2M | ||
| Q2 25 | $82.4M | $303.3M | ||
| Q1 25 | $65.0M | $318.5M | ||
| Q4 24 | $69.1M | $301.1M | ||
| Q3 24 | $51.6M | $305.5M | ||
| Q2 24 | $73.8M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | — | $41.6M | ||
| Q3 25 | $-31.3M | $45.8M | ||
| Q2 25 | $-12.7M | $36.1M | ||
| Q1 25 | $-40.5M | $42.1M | ||
| Q4 24 | — | $35.5M | ||
| Q3 24 | $-29.5M | $29.7M | ||
| Q2 24 | $-61.9M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 50.6% | 16.1% | ||
| Q3 25 | -11.4% | 18.4% | ||
| Q2 25 | 8.6% | 16.3% | ||
| Q1 25 | -34.0% | 18.1% | ||
| Q4 24 | -6.4% | 14.7% | ||
| Q3 24 | -31.0% | 13.9% | ||
| Q2 24 | 3.5% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | — | 12.6% | ||
| Q3 25 | -35.9% | 13.9% | ||
| Q2 25 | -15.4% | 11.9% | ||
| Q1 25 | -62.2% | 13.2% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | -57.2% | 9.7% | ||
| Q2 24 | -83.9% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $0.32 | $0.68 | ||
| Q3 25 | $-0.16 | $0.74 | ||
| Q2 25 | $-0.06 | $0.57 | ||
| Q1 25 | $-0.21 | $0.65 | ||
| Q4 24 | $-0.14 | $0.55 | ||
| Q3 24 | $-0.15 | $0.46 | ||
| Q2 24 | $-0.33 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | $990.8M |
| Stockholders' EquityBook value | $-302.0M | $2.2B |
| Total Assets | $465.9M | $15.7B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $-302.0M | $2.2B | ||
| Q3 25 | $-451.4M | $2.2B | ||
| Q2 25 | $-433.5M | $2.2B | ||
| Q1 25 | $-426.2M | $2.2B | ||
| Q4 24 | $-388.7M | $2.2B | ||
| Q3 24 | $-370.2M | $2.2B | ||
| Q2 24 | $-344.2M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $465.9M | $15.8B | ||
| Q3 25 | $364.0M | $15.6B | ||
| Q2 25 | $347.1M | $15.4B | ||
| Q1 25 | $324.0M | $15.8B | ||
| Q4 24 | $343.8M | $16.3B | ||
| Q3 24 | $314.1M | $15.9B | ||
| Q2 24 | $352.3M | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $-38.7M | ||
| Q3 25 | $-4.3M | $273.0M | ||
| Q2 25 | $-31.4M | $-234.6M | ||
| Q1 25 | $-22.6M | $5.8M | ||
| Q4 24 | $-35.0M | $273.9M | ||
| Q3 24 | $-35.3M | $515.6M | ||
| Q2 24 | $-7.2M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-55.5M | ||
| Q3 25 | — | $271.0M | ||
| Q2 25 | — | $-234.6M | ||
| Q1 25 | — | $5.0M | ||
| Q4 24 | — | $266.8M | ||
| Q3 24 | $-35.5M | $513.8M | ||
| Q2 24 | $-7.3M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | -16.8% | ||
| Q3 25 | — | 82.1% | ||
| Q2 25 | — | -77.4% | ||
| Q1 25 | — | 1.6% | ||
| Q4 24 | — | 88.6% | ||
| Q3 24 | -68.7% | 168.2% | ||
| Q2 24 | -9.9% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 5.1% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.3% | 0.6% | ||
| Q2 24 | 0.1% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.93× | ||
| Q3 25 | — | 5.96× | ||
| Q2 25 | — | -6.50× | ||
| Q1 25 | — | 0.14× | ||
| Q4 24 | — | 7.71× | ||
| Q3 24 | — | 17.36× | ||
| Q2 24 | — | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
